Alcentra Capital (ABDC) Expected to Announce Quarterly Sales of $8.23 Million

Equities analysts forecast that Alcentra Capital (NASDAQ:ABDC) will report $8.23 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Alcentra Capital’s earnings, with the highest sales estimate coming in at $8.84 million and the lowest estimate coming in at $7.92 million. Alcentra Capital posted sales of $9.20 million during the same quarter last year, which suggests a negative year-over-year growth rate of 10.5%. The company is scheduled to issue its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Alcentra Capital will report full-year sales of $31.15 million for the current year, with estimates ranging from $28.80 million to $32.35 million. For the next fiscal year, analysts anticipate that the company will report sales of $31.74 million per share, with estimates ranging from $28.10 million to $33.85 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Alcentra Capital.

How to Become a New Pot Stock Millionaire

Alcentra Capital (NASDAQ:ABDC) last issued its quarterly earnings results on Wednesday, March 14th. The asset manager reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $8.20 million during the quarter, compared to the consensus estimate of $7.77 million. Alcentra Capital had a positive return on equity of 10.56% and a negative net margin of 57.28%.

A number of analysts have weighed in on the company. Keefe, Bruyette & Woods set a $7.00 target price on Alcentra Capital and gave the stock a “hold” rating in a research note on Thursday, March 15th. UBS upgraded Alcentra Capital from an “underperform” rating to a “market perform” rating in a research note on Thursday, January 11th. ValuEngine upgraded Alcentra Capital from a “hold” rating to a “buy” rating in a research note on Thursday, March 22nd. Finally, Raymond James upgraded Alcentra Capital from an “underperform” rating to a “market perform” rating in a research note on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Alcentra Capital presently has an average rating of “Hold” and an average target price of $12.00.

Shares of ABDC opened at $6.72 on Thursday. Alcentra Capital has a 52-week low of $5.93 and a 52-week high of $14.61. The firm has a market capitalization of $95.18, a P/E ratio of 5.17 and a beta of 0.57.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 4th. Shareholders of record on Friday, March 30th were paid a $0.18 dividend. The ex-dividend date of this dividend was Wednesday, March 28th. This represents a $0.72 dividend on an annualized basis and a yield of 10.71%. Alcentra Capital’s payout ratio is 54.55%.

In other Alcentra Capital news, insider Branko Krmpotic bought 10,000 shares of Alcentra Capital stock in a transaction on Tuesday, March 20th. The shares were acquired at an average price of $6.15 per share, for a total transaction of $61,500.00. Following the completion of the purchase, the insider now directly owns 14,000 shares in the company, valued at approximately $86,100. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders acquired 14,750 shares of company stock worth $91,788. Insiders own 4.96% of the company’s stock.

Several institutional investors have recently made changes to their positions in ABDC. Stilwell Value LLC purchased a new position in shares of Alcentra Capital during the fourth quarter valued at $8,701,000. Pacific Ridge Capital Partners LLC purchased a new position in shares of Alcentra Capital during the fourth quarter valued at $1,171,000. Bramshill Investments LLC purchased a new position in shares of Alcentra Capital during the fourth quarter valued at $512,000. Caxton Corp purchased a new position in shares of Alcentra Capital during the fourth quarter valued at $500,000. Finally, Wasatch Advisors Inc. increased its stake in shares of Alcentra Capital by 151.5% during the fourth quarter. Wasatch Advisors Inc. now owns 85,813 shares of the asset manager’s stock valued at $720,000 after buying an additional 51,689 shares during the period. Hedge funds and other institutional investors own 34.87% of the company’s stock.

WARNING: This story was originally posted by Macon Daily and is the property of of Macon Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://macondaily.com/2018/04/19/alcentra-capital-abdc-expected-to-announce-quarterly-sales-of-8-23-million.html.

About Alcentra Capital

Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.

Get a free copy of the Zacks research report on Alcentra Capital (ABDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply